- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07939321
Cardiovascular Risk and Outcomes in Patients With Cancer: The TRACE-Cancer Study (TRACE-Cancer)
Cardiovascular Risk Stratification, Clinical Outcomes, and Prevention in Patients With Cancer: A Nationwide Multicenter Retrospective and Prospective Cohort Study
The goal of this observational study is to investigate cardiovascular risks and long-term outcomes in adults with cancer in China. The main questions it aims to answer are:What is the risk of major adverse cardiovascular events (MACE) in patients with different types of cancer and anticancer treatments?Can clinical characteristics, cardiovascular assessments, and biomarkers help predict cardiovascular events and identify high-risk patients?This nationwide, multicenter study includes both retrospective and prospective cohorts. Researchers will collect clinical information from medical records and follow participants over time to assess cardiovascular health and outcomes.Participants in the prospective cohort will undergo cardiovascular assessments and follow-up as part of their clinical care. No experimental treatments will be assigned.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
The TRACE-Cancer Study is a nationwide, multicenter, observational cohort study designed to evaluate cardiovascular risks and long-term outcomes in adults with cancer.The study includes a retrospective cohort of patients diagnosed between January 2018 and June 2026 and a prospective cohort enrolled from June 2026, with follow-up planned through December 2036.Clinical data will include cancer characteristics, anticancer treatments, cardiovascular risk factors, medical history, laboratory tests, cardiac imaging, and biomarkers. The primary outcome is major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal stroke, and serious arrhythmias. Secondary outcomes include all-cause mortality, cancer-specific mortality, other cardiovascular complications, and changes in cardiac function.The study will also develop and validate cardiovascular risk prediction models to support early identification and prevention of cardiovascular complications in patients with cancer. All treatment decisions will follow routine clinical practice without study-assigned interventions.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Guoliang Li
- Puhelinnumero: 0086-2985323868
- Sähköposti: guoliangli@xjtu.edu.cn
Tutki yhteystietojen varmuuskopiointi
- Nimi: Shi Tao
- Puhelinnumero: 0086-2985323865
- Sähköposti: shitao068@xjtu.edu.cn
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
The study population consists of adults aged 18 years or older with pathologically or cytologically confirmed malignancies receiving cancer-related care at participating medical centers across China. The study includes two cohorts: a retrospective cohort of patients diagnosed and treated between January 2018 and June 2026, and a prospective cohort enrolling eligible patients from June 2026 onward. Participants will be recruited from general hospitals, cancer centers, and cardiovascular centers. All cancer types and stages are eligible, regardless of anticancer treatment or baseline cardiovascular status. Clinical information and long-term cardiovascular outcomes will be collected using standardized procedures. Biospecimen availability is not required for enrollment.
Kuvaus
Inclusion Criteria:
- Adults aged 18 years or older.
- Patients with a pathologically or cytologically confirmed diagnosis of malignancy.
- Patients receiving cancer-related diagnosis, treatment, clinical assessment, or follow-up at participating centers.
- For the retrospective cohort, availability of traceable clinical records, including medical history, pathology reports, treatment information, or follow-up data.
- For the prospective cohort, provision of informed consent by the participant or legally authorized representative, in accordance with applicable ethical requirements.
- Availability of baseline clinical information and the ability to obtain follow-up information through clinical records, outpatient visits, hospitalization records, telephone contact, or other approved sources.
Exclusion Criteria:
- Inability to confirm a diagnosis of malignancy.
- For the retrospective cohort, insufficient essential clinical information to establish baseline status or ascertain the primary outcome.
- For the prospective cohort, refusal to provide informed consent when required.
- Duplicate enrollment of the same participant at the same center; only the first eligible record will be retained.
- Other circumstances determined by the investigators to prevent appropriate participation or reliable follow-up.
Additional Consideration:
Patients will not be excluded based on cancer type, cancer stage, anticancer treatment modality, pre-existing cardiovascular conditions, comorbidities, or expected survival. The availability of biological specimens is not required for enrollment, and participants without available biospecimens will remain eligible for the clinical cohort.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: OTHER
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Retrospective Cohort
Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who received medical care at participating centers between January 2018 and June 2026. Clinical characteristics, anticancer treatments, cardiovascular risk factors, and long-term outcomes will be collected retrospectively from existing medical records and available follow-up data. |
|
Prospective Cohort
Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who are prospectively enrolled at participating centers beginning in June 2026. Clinical characteristics, anticancer treatments, cardiovascular assessments, and outcomes will be collected at baseline and during longitudinal follow-up through December 2036. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to First Major Adverse Cardiovascular Event (MACE)
Aikaikkuna: From baseline to the first qualifying event or the end of follow-up, up to 10 years.
|
Time from baseline to the first occurrence of a major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal ischemic or hemorrhagic stroke, or serious arrhythmia. Serious arrhythmias include sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. The first qualifying event will be identified through medical records and follow-up information and adjudicated according to standardized diagnostic criteria. |
From baseline to the first qualifying event or the end of follow-up, up to 10 years.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to All-Cause Mortality
Aikaikkuna: From baseline to death or the end of follow-up, up to 10 years.
|
Time from baseline to death from any cause. Death events and dates will be identified using hospital medical records, available death registration information, and follow-up records. The cumulative incidence and time to all-cause mortality will be assessed during follow-up. |
From baseline to death or the end of follow-up, up to 10 years.
|
|
Time to Cancer-Specific Mortality
Aikaikkuna: From baseline to cancer-related death or the end of follow-up, up to 10 years.
|
Time from baseline to death attributed to the underlying malignancy or cancer-related complications. Cancer-specific mortality will be determined based on available medical records, documented causes of death, and follow-up information. Deaths from other causes will be treated as competing events in the analysis of cancer-specific mortality. |
From baseline to cancer-related death or the end of follow-up, up to 10 years.
|
|
Time to Cardiovascular Death
Aikaikkuna: From baseline to cardiovascular death or the end of follow-up, up to 10 years.
|
Time from baseline to death attributed to cardiovascular causes, including fatal myocardial infarction, heart failure, stroke, sudden cardiac death, or other cardiovascular conditions. Cardiovascular death will be determined using available medical records, documented causes of death, and standardized adjudication criteria. Noncardiovascular deaths will be treated as competing events. |
From baseline to cardiovascular death or the end of follow-up, up to 10 years.
|
|
Time to First Nonfatal Myocardial Infarction
Aikaikkuna: From baseline to the first nonfatal myocardial infarction or the end of follow-up, up to 10 years.
|
Time from baseline to the first nonfatal myocardial infarction during follow-up. Myocardial infarction will be identified from clinical records and hospitalization data and confirmed according to standardized diagnostic criteria, including clinical presentation, cardiac troponin measurements, electrocardiographic findings, and available cardiac imaging or coronary angiographic evidence. |
From baseline to the first nonfatal myocardial infarction or the end of follow-up, up to 10 years.
|
|
Time to First Hospitalization for Heart Failure
Aikaikkuna: From baseline to the first hospitalization for heart failure or the end of follow-up, up to 10 years.
|
Time from baseline to the first hospitalization for newly diagnosed or worsening heart failure requiring inpatient treatment. Heart failure events will be identified through hospitalization records and confirmed using clinical symptoms, signs, cardiac imaging findings, laboratory results, and standardized diagnostic criteria. |
From baseline to the first hospitalization for heart failure or the end of follow-up, up to 10 years.
|
|
Time to First Nonfatal Stroke
Aikaikkuna: From baseline to the first nonfatal stroke or the end of follow-up, up to 10 years.
|
Time from baseline to the first nonfatal stroke, including ischemic and hemorrhagic stroke. Stroke events will be identified through clinical records, hospitalization data, and available neuroimaging findings and confirmed according to standardized diagnostic criteria. |
From baseline to the first nonfatal stroke or the end of follow-up, up to 10 years.
|
|
Time to First Serious Arrhythmia
Aikaikkuna: From baseline to the first qualifying serious arrhythmia or the end of follow-up, up to 10 years.
|
Time from baseline to the first occurrence of a serious arrhythmia, including sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. Events will be identified through electrocardiograms, ambulatory electrocardiographic monitoring, implanted cardiac device records, hospitalization records, and clinical documentation. |
From baseline to the first qualifying serious arrhythmia or the end of follow-up, up to 10 years.
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Plasma N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration
Aikaikkuna: Baseline and available follow-up assessments through 10 years.
|
Change in plasma NT-proBNP concentration from baseline to follow-up, measured using validated clinical laboratory immunoassays and reported in pg/mL. Absolute changes in NT-proBNP concentration will be calculated among participants with available baseline and follow-up measurements. Exploratory analyses will examine the relationship between NT-proBNP levels and cardiovascular outcomes, particularly heart failure events, in participants with available clinical data and biospecimens. |
Baseline and available follow-up assessments through 10 years.
|
|
Change in Circulating Cardiac Troponin Concentration
Aikaikkuna: Baseline and available follow-up assessments through 10 years.
|
Change in circulating cardiac troponin concentration from baseline to follow-up, measured using validated clinical laboratory cardiac troponin assays and reported in assay-specific concentration units. Absolute changes will be evaluated among participants with available baseline and follow-up measurements. Exploratory analyses will investigate the relationship between circulating cardiac troponin concentrations and cardiovascular outcomes, particularly myocardial injury and major adverse cardiovascular events. |
Baseline and available follow-up assessments through 10 years.
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Guoliang Li, First Affiliated Hospital Xi'an Jiaotong University
- Päätutkija: Tao Shi, First Affiliated Hospital Xi'an Jiaotong University
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- XJTU1AF2026LSYY-0455
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .